Biohaven Pharmaceutical Holding Debt to Equity Ratio 2016-2022 | BHVN

Current and historical debt to equity ratio values for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Biohaven Pharmaceutical Holding debt/equity for the three months ending March 31, 2022 was 0.00.
Biohaven Pharmaceutical Holding Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $1.84B $-0.47B -3.94
2021-12-31 $1.82B $-0.74B -2.45
2021-09-30 $1.72B $-0.59B -2.91
2021-06-30 $1.30B $-0.46B -2.85
2021-03-31 $1.28B $-0.28B -4.61
2020-12-31 $1.08B $-0.39B -2.75
2020-09-30 $1.00B $-0.21B -4.66
2020-06-30 $0.46B $-0.04B -12.96
2020-03-31 $0.41B $0.12B 3.37
2019-12-31 $0.35B 0.00
2019-09-30 $0.32B $0.12B 2.69
2019-06-30 $0.30B $0.19B 1.63
2019-03-31 $0.15B $0.10B 1.53
2018-12-31 $0.14B $0.15B 0.92
2018-09-30 $0.13B $0.07B 1.96
2018-06-30 $0.12B $0.12B 1.01
2018-03-31 $0.02B $0.11B 0.17
2017-12-31 $0.02B $0.13B 0.11
2017-09-30 $0.03B $0.16B 0.18
2017-06-30 $0.02B $0.19B 0.11
2017-03-31 $0.04B $0.02B 1.96
2016-12-31 $0.03B $-0.00B -16.32
2016-09-30 $0.00B $0.00B 0.00
2016-06-30 $0.00B $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B $0.00B 0.74
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.248B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00